scholarly journals Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study

2018 ◽  
Vol Volume 14 ◽  
pp. 1213-1218 ◽  
Author(s):  
Katsuhiko Nakatsukasa ◽  
Hiroshi Koyama ◽  
Yoshimi Ouchi ◽  
Koichi Sakaguchi ◽  
Yoshifumi Fujita ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Bone Mineral ◽  
Phase Ii ◽  
Aromatase Inhibitors ◽  
Phase Ii Study ◽  
Japanese Women ◽  
Mineral Density ◽  
Subgroup Analyses ◽  
Breast Cancer Subgroup

Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer

2018 ◽  
Vol 37 (2) ◽  
pp. 301-306 ◽  
Author(s):  
Katsuhiko Nakatsukasa ◽  
Hiroshi Koyama ◽  
Yoshimi Ouchi ◽  
Kouichi Sakaguchi ◽  
Yoshifumi Fujita ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Japanese Women ◽  
Mineral Density

scholarly journals Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors

2017 ◽  
Vol 13 (5) ◽  
pp. e505-e515 ◽  
Author(s):  
Jamie Stratton ◽  
Xin Hu ◽  
Pamela R. Soulos ◽  
Amy J. Davidoff ◽  
Lajos Pusztai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Early Stage ◽  
Mineral Density ◽  
Dxa Scan ◽  
Bone Mineral Density Testing

Purpose: In postmenopausal women with breast cancer treated with aromatase inhibitors (AIs), most expert panels advise baseline bone mineral density testing with a dual-energy x-ray absorptiometry (DXA) scan repeated every 1 to 2 years. How often this recommendation is followed is unclear. Methods: We performed a retrospective analysis of women with stage I to III breast cancer who started AI therapy from January 1, 2008, to December 31, 2010, with follow-up through December 31, 2012, by using the SEER-Medicare database. Selection criteria included AI use for ≥ 6 months and no recent osteoporosis diagnosis or bisphosphonate use. We used multivariable logistic regression to investigate associations between patient characteristics and receipt of a baseline DXA scan. In patients who continued AI treatment, we assessed rates of follow-up scans. Results: In the sample of 2,409 patients (median age, 74 years), 51.0% received a baseline DXA scan. Demographic characteristics associated with the absence of a baseline DXA scan were older age (85 to 94 years v 67 to 69 years; odds ratio [OR], 0.62; 95% CI, 0.42 to 0.92) and black v white race (OR, 0.68; 95% CI, 0.47 to 0.97). Among patients who underwent a baseline DXA scan and continued AI for 3 years, 28.0% had a repeat DXA scan within 2 years and 65.9% within 3 years. In aggregate, of the 1,164 patients who continued with AI treatment for 3 years, only 34.5% had both a baseline and at least one DXA scan during the 3-year follow-up period. Conclusion: The majority of older Medicare beneficiaries with breast cancer treated with AIs do not undergo appropriate bone mineral density evaluation.

scholarly journals FRI0549 Impact of chemotherapy on bone mineral density in postmenopathic women with breast cancer in treatment with aromatase inhibitors

2017 ◽  
Author(s):  
J Loarce-Martos ◽  
WA Sifuentes Giraldo ◽  
LV Maldonado Romero ◽  
M Ahijόn Lana ◽  
C Velázquez Arce ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Mineral Density

scholarly journals The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors

Obesity ◽  
2016 ◽  
Vol 25 (2) ◽  
pp. 346-351 ◽  
Author(s):  
Gwendolyn A. Thomas ◽  
Brenda Cartmel ◽  
Maura Harrigan ◽  
Martha Fiellin ◽  
Scott Capozza ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Body Composition ◽  
Cancer Survivors ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Breast Cancer Survivors ◽  
Mineral Density

scholarly journals Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer

Medicine ◽  
2019 ◽  
Vol 98 (32) ◽  
pp. e16770 ◽  
Author(s):  
Koichi Sakaguchi ◽  
Hisako Ono ◽  
Katsuhiko Nakatsukasa ◽  
Takashi Ishikawa ◽  
Yoshie Hasegawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Mineral Density ◽  
Normal Bone ◽  
Normal Bone Mineral Density
Sign in / Sign up

Export Citation Format

Share Document